Immunogenic peptides and methods of use

Details Immunogenic peptides and methods of use Immunogenic peptides and methods of use

2011-03-22

2011-03-22

Reddig, Peter J (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S328000, C536S023100, C536S023500, C514S002600, C514S04400A

Reexamination Certificate

active

07910692

ABSTRACT:
The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.

REFERENCES:
patent: 6045802 (2000-04-01), Schlom et al.
patent: 6893869 (2005-05-01), Schlom et al.
patent: 7399827 (2008-07-01), Pastan et al.
patent: 2004/0019195 (2004-01-01), Scholm et al.
patent: 2004/0171796 (2004-09-01), Schlom et al.
patent: 2005/0054575 (2005-03-01), Schlom et al.
patent: 2005/0186180 (2005-08-01), Schlom et al.
patent: WO 00/12706 (2000-04-01), None
Dudley and Rosenberg (Nature Reviews Cancer 3:666-675).
Celis (J. of Clinical Investigation, 2002, 110:1765-1768).
Marincola et al. (Trends in Immunology, Jun. 2003, 334-341).
Harlin et al. (Caner Immunol. Immunotherap. 2006, 55:1185-1197).
Gura (Science, 1997, 278:1041-1042).
Kaiser (Science 2006, 31: 1370).
Janeway et al. (Immunobiology 5, www.garlandscience.com, Antigen recognition by T cells, 2001).
Brinkmann, U. et al., “Novel Genes in the PAGE and GAGE Family of Tumor Antigens Found by Homology Walking in the dbEST Database,”Cancer Research59:1445-1448, Apr. 1, 1999.
Brinkmann, U. et al., “PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus,”Proc. Nat. Acad. Sci. USA95:10757-10762, Sep. 1998.
Brown, K. L. and Hancock, R. E.W., “Cationic host defense (antimicrobial) peptides,”Current Opinion in Immunology18:24-30, 2006.
Butt, T. R., et al., “SUMO fusion technology for difficult-to-express proteins,”Protein Expression&Purification43:1-9, 2005.
De Smet, K. and Contreras, R., “Human antimicrobial peptides: defensins, cathelicidins and histatins,”Biotecnology Letters27:1337-1347, Mar. 2005.
Iavarone, C. et al., “PAGE4 is a Cytoplasmic Protein that is Expressed in Normal Prostate and in Prostate Cancers,”Molecular Cancer Therapeutics1:329-335, Mar. 2002.
Malakhov, M. et al., “SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins,”Journal of Structural and Functional Genomics5:75-86, 2004.
Marblestone J. et al., “Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO,”Protein Sci.15:1-8, 2005.
Yokokawa et al., “Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy,”Proceedings of the American Association for Cancer Research Annual Meeting; 47:530-531, 2006.
Zhong et al., “Tandem repeatmhBD2gene enhance the soluble fusion expression of hBD2 inEscherichia coli,” Appl Microbiol Biotechnol71:661-667, 2006.
Zuo et al., “Enhanced expression and purification of membrane proteins by SUMO fusion inEscherichia coli,” Journal of Structural and Functional Genomics6:103-111, 2005.
Zuo et al., “Expression and purification of SARS coronavirus proteins using SUMO-fusions,”Protein Expression and Purification42:100-110, 2005.
Lechleider et al., “Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 is Used as an Adjuvant,”Clin. Cancer Res. 14(16):5284-5291 (Aug. 15, 2008).
Yokokawa et al., “Identification of Cytotoxic T-lymphocyte Epitope(s) and its Agonist Epitope(s) of a Novel Target for Vaccine Therapy (PAGE4),”Int. J Cancer. 121:595-605 (2007).

Affiliated with

Also associated with

Rating

Immunogenic peptides and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogenic peptides and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic peptides and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2772477